Skip to main content
SpringerLink
Log in
Book cover

Resistant Hypertension in Chronic Kidney Disease pp 25–38Cite as

Apparent Treatment-Resistant Hypertension and Chronic Kidney Disease: Another Cardiovascular–Renal Syndrome?

  • Chapter
  • First Online:

Abstract

Arterial hypertension is the most frequent comorbid condition of chronic kidney disease (CKD) affecting almost 80% of CKD patients. It accelerates progression of CKD and increases the cardiovascular risk of CKD patients substantially. Many CKD patients have treatment-resistant or difficult-to-treat hypertension leading to a high incidence of end-organ damage. Particularly, target-organ damage to the heart is an important determinant of prognosis that can be present from the very onset of CKD or develop during the course and progression of CKD. From this perspective, arterial hypertension with its high prevalence of treatment resistance in CKD can be coined as another cardiovascular–renal syndrome with a characteristic bidirectional interaction. Adequate treatment of arterial hypertension and overcoming of treatment resistance are of utmost importance for CKD patients to halt progression of CKD and to prevent cardiovascular damage, ultimately resulting in an improved outcome and survival.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S13–20.

    Article  CAS  PubMed  Google Scholar 

  2. Buckalew VM, Berg RL, Wang SR, Porush JG, Rauch S, Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis. 1996;28(6):811–21.

    Article  PubMed  Google Scholar 

  3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–19.

    Article  CAS  PubMed  Google Scholar 

  4. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58.

    Article  PubMed  PubMed Central  Google Scholar 

  5. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.

    Article  PubMed  Google Scholar 

  6. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–74.

    Article  CAS  PubMed  Google Scholar 

  7. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42.

    Article  PubMed  PubMed Central  Google Scholar 

  8. De Nicola L, Borrelli S, Gabbai FB, Chiodini P, Zamboli P, Iodice C, et al. Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease. Kidney Blood Press Res. 2011;34(1):58–67.

    Article  PubMed  Google Scholar 

  9. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8(9):1583–90.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–39.

    Article  PubMed  Google Scholar 

  11. De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61(24):2461–7.

    Article  PubMed  Google Scholar 

  12. Kannel WB. Fifty years of Framingham study contributions to understanding hypertension. J Hum Hypertens. 2000;14(2):83–90.

    Article  CAS  PubMed  Google Scholar 

  13. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 Suppl 1):S117–31.

    Article  CAS  PubMed  Google Scholar 

  14. Wali RK, Henrich WL. Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin. 2005;23(3):343–62.

    Article  PubMed  Google Scholar 

  15. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63.

    Article  PubMed  Google Scholar 

  16. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.

    Article  PubMed  Google Scholar 

  17. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1599–605.

    Article  PubMed  Google Scholar 

  18. Mizobuchi M, Towler T, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20(7):1453–64.

    Article  CAS  PubMed  Google Scholar 

  19. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581–98.

    Article  PubMed  Google Scholar 

  21. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    Article  CAS  PubMed  Google Scholar 

  22. Hung SC, Kuo KL, Peng CH, Wu CH, Lien YC, Wang YC, Tarng DC. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int. 2014;85(3):703–9.

    Article  CAS  PubMed  Google Scholar 

  23. Schork A, Woern M, Kalbacher H, Voelter W, Nacken R, Bertog M, et al. Association of plasminuria with overhydration in CKD patients. Clin J Am Soc Nephrol. 2016;11(5):761–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Passero CJ, Hughey RP, Kleyman TR. New role for plasmin in sodium homeostasis. Curr Opin Nephrol Hypertens. 2010;19(1):13–9.

    Google Scholar 

  25. Andersen H, Friis UG, Hansen PB, Svenningsen P, Henriksen JE, Jensen BL. Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells. Nephrol Dial Transplant. 2015;30(5):781–9.

    Article  CAS  PubMed  Google Scholar 

  26. Smyth A, O'Donnell MJ, Yusuf S, Clase CM, Teo KK, Canavan M, Reddan DN, Mann JF. Sodium intake and renal outcomes: a systematic review. Am J Hypertens. 2014;27(10):1277–84.

    Article  PubMed  Google Scholar 

  27. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62(1):168–74.

    Article  CAS  PubMed  Google Scholar 

  29. Shimbo D, Kent ST, Diaz KM, Huang L, Viera AJ, Kilgore M, et al. The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010. J Am Soc Hypertens. 2014;8(12):891–7.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311(21):2216–24.

    Article  PubMed  Google Scholar 

  31. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–45.

    Article  CAS  PubMed  Google Scholar 

  32. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(1008):2059–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich). 2004;6(5):283–7.

    Article  Google Scholar 

Download references

Disclosure

There are no relationships with companies that may have a financial interest in the information contained in this manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology and Clinical Chemistry, University Hospital Tübingen, Tübingen, Germany

    Ferruh Artunc

  2. Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, Otfried-Mueller-Strasse 10, 72076, Tübingen, Germany

    Ferruh Artunc

  3. German Center for Diabetes Research (DZD), Otfried-Mueller-Strasse 10, 72076, Tübingen, Germany

    Ferruh Artunc

Authors
  1. Ferruh Artunc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ferruh Artunc .

Editor information

Editors and Affiliations

  1. Grigore T. Popa University of Medicine, Iaşi, Romania

    Adrian Covic

  2. Department of Medicine, Division of Nephrology, University School of Medicine, Istanbul, Turkey

    Mehmet Kanbay

  3. Section of Nephrology, University of Illinois at Chicago College of Medicine/Advocate Christ Medical Center, Oak Lawn, Illinois, USA

    Edgar V. Lerma

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Artunc, F. (2017). Apparent Treatment-Resistant Hypertension and Chronic Kidney Disease: Another Cardiovascular–Renal Syndrome?. In: Covic, A., Kanbay, M., Lerma, E. (eds) Resistant Hypertension in Chronic Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-56827-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56827-0_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56825-6

  • Online ISBN: 978-3-319-56827-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation